Gilead Sciences, Inc.

Gilead Connecticut, Inc.

Neurogen Corporation

Cgi Pharmaceuticals, Inc.

Genentech, Inc.

Kronos Bio, Inc.

Genetech, Inc.

Pfizer Corporation

Novartis International Pharmaceutical, Ltd.

Cellular Genomics, Inc.

Kevin S Currie

Scott A Mitchell

Peter A Blomgren

Jeffrey E Kropf

Jianjun Xu

Seung H Lee

Zhongdong Zhao

Aaron C Schmitt

Jennifer R Lo

Douglas Gregory Stafford

Jun Yuan

Jayaraman Chandrasekhar

Jin-Ming Xiong

George D Maynard

Sundaramoorthi Swaminathan

Kirk L Stevens

Pavel E Zhichkin

Christian Gege

Xiaojing Wang

Wendy B Young

Leena Patel

Kyungae Lee

Manuka Ghosh

Yasamin Moazami

Pamela Ann Albaugh

Jennifer Anne Treiberg

Robert W DeSimone

Christopher T Clark

Stephane Perreault

James William Darrow

Jason K Perry

Douglas A Pippin

Taryn Campbell

Nicole Nava

Natalie Seeger

Daniel Fred Ortwine

Guolin Cai

George P Luke

Suet Chung Yeung

Julian Andrew Codelli

Julie Farand

Kassandra F Sedillo

Antonio J M Barbosa

Alan J Hutchison

William John Watkins

He Zhao

Honglu Zhang

Ravi Krishnamoorthy

John O Link

Darryl Kato

David M Armistead

Linda M Gustavson

Jiayao Li

Guiying Li

Nian Liu

Antonio J M Barbosa, Jr

Soumya Mitra

James P Harding

Ling Hong Xie

Jeff A Zablocki

Hyung-Jung Pyun

Chandrasekar Venkataramani

Scott E Lazerwith

Zheng-Yu Yang

Sheila M Zipfel

Gregory Notte

Juan A Guerrero

Zhimin Du

Adam James Schrier

Michael Sangi

Ashley Anne Katana

David R Brittelli

Spiros Liras

Linghong Xie

Qin Guo

Martin Patrick Allen

Julie A Di Paolo

Lawrence Albert Vincent

Daniel Yohannes

Antonio J Barbosa

Astrid Clarke

Scott D Schroeder

Winston C Tse

Eda Y Canales

Paul Chen

John M Peterson

Joshua A Kaplan

Samuel E Metobo

Olaf Kinzel

Qiaoyin Wu

Roland D Saito

Nathan D Shapiro

Evangelos Aktoudianakis

Claus Kremoser

Yunfeng Eric Hu

Patrick J Salvo

Heath A Weaver

Stephen D Holmbo

Jesse M Jacobsen

Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, together with a pharmaceutically acceptable excipient thereof, and a method of treating cancer with the same.

PARP7 inhibitors

The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

FXR (NR1H4) modulating compounds

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2:

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

Quinoline derivatives

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.

Compounds for inhibition of &#x3b1;4 &#x3b2;7 integrin

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2: 

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

Compounds for inhibition of alpha 4 beta 7 integrin

The present disclosure relates generally to compounds that bind to FXR and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

Compounds for inhibition of &#x3b1;4&#x3b2;7 integrin

Imidazopyridine derivatives

Certain imidazopyridines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

Imidazopyridines Syk inhibitors

Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

Growing community of inventors

North Branford, CT, United States of America

Kevin S Currie